Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae
Clin Mol Hepatol. 2017;23(1):51-56.   Published online 2017 Mar 16     DOI: https://doi.org/10.3350/cmh.2016.0053
Citations to this article as recorded by Crossref logo
Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea
Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon-Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok-Hwan Kim, Myeong Jun Song, Pil Soo Sung,
Journal of Medical Virology.2019;[Epub]     CrossRef
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo FocĂ , Carlo Torti
Clinical and Molecular Hepatology.2019; 25(1): 30.     CrossRef
Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia
F. Ji, B. Wei, Y. H. Yeo, E. Ogawa, B. Zou, C. D. Stave, Z. Li, S. Dang, N. Furusyo, R. C. Cheung, M. H. Nguyen
Alimentary Pharmacology & Therapeutics.2018; 47(5): 550.     CrossRef
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients
S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.-Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.-H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K
Journal of Viral Hepatitis.2018; 25(10): 1189.     CrossRef
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
Gut and Liver.2018; 12(3): 324.     CrossRef
Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
Petra E de Ruiter, Yashna Gadjradj, Robert J de Knegt, Herold J Metselaar, Jan NM Ijzermans, Luc JW van der Laan
World Journal of Transplantation.2018; 8(5): 156.     CrossRef
Asunaprevir/daclatasvir
Reactions Weekly.2017; 1653(1): 56.     CrossRef
Global elimination of hepatitis C virus infection: Progresses and the remaining challenges
Reza Taherkhani, Fatemeh Farshadpour
World Journal of Hepatology.2017; 9(33): 1239.     CrossRef